189 related articles for article (PubMed ID: 30352285)
1. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
Dal Negro R; Pozzi E; Cella SG
Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
[TBL] [Abstract][Full Text] [Related]
2. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
3. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
4. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Olivieri D; Del Donno M; Casalini A; D'Ippolito R; Fregnan GB
Respiration; 1991; 58(2):91-4. PubMed ID: 1862257
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
7. Mucolytic and antitussive effects of erdosteine.
Hosoe H; Kaise T; Ohmori K; Isohama Y; Kai H; Takahama K; Miyata T
J Pharm Pharmacol; 1999 Aug; 51(8):959-66. PubMed ID: 10504037
[TBL] [Abstract][Full Text] [Related]
8. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
9. Erdosteine for COPD exacerbations.
Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
[TBL] [Abstract][Full Text] [Related]
10. Mucoactive medications and airway disease.
Majima Y
Paediatr Respir Rev; 2002 Jun; 3(2):104-9. PubMed ID: 12297055
[TBL] [Abstract][Full Text] [Related]
11. Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
Hosoe H; Kaise T; Ohmori K
J Pharmacol Toxicol Methods; 1998 Oct; 40(3):165-71. PubMed ID: 10334633
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
Balli F; Bergamini B; Calistru P; Ciofu EP; Domenici R; Doros G; Dragomir D; Gherghina I; Iordachescu F; Murgoci G; Orasanu D; Plesca D; Vaccaro A; Assereto R
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):16-22. PubMed ID: 17256446
[TBL] [Abstract][Full Text] [Related]
13. Effect of erdosteine and its metabolites on tracheobronchial mucus production and transport.
Scuri R; Giannetti P; Paesano A
Drugs Exp Clin Res; 1988; 14(11):693-8. PubMed ID: 3246214
[TBL] [Abstract][Full Text] [Related]
14. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
[TBL] [Abstract][Full Text] [Related]
15. Erdosteine.
Dechant KL; Noble S
Drugs; 1996 Dec; 52(6):875-81; discussion 882. PubMed ID: 8957158
[TBL] [Abstract][Full Text] [Related]
16. Acute and Chronic Effects of Oral Erdosteine on Ciliary Beat Frequency, Cough Sensitivity and Airway Reactivity.
Pappová L; Kazimierová I; Jošková M; Šutovská M; Fraňová S
Adv Exp Med Biol; 2018; 1023():1-10. PubMed ID: 28730380
[TBL] [Abstract][Full Text] [Related]
17. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):248-52. PubMed ID: 12053601
[TBL] [Abstract][Full Text] [Related]
18. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
[TBL] [Abstract][Full Text] [Related]
19. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
20. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
